2019
Platinum‐based regimens versus cetuximab in definitive chemoradiation for human papillomavirus‐unrelated head and neck cancer
Beckham TH, Barney C, Healy E, Wolfe AR, Branstetter A, Yaney A, Riaz N, McBride SM, Tsai CJ, Kang J, Yu Y, Chen L, Sherman E, Dunn L, Pfister DG, Tan J, Rupert R, Bonomi M, Zhang Z, Lobaugh SM, Grecula JC, Mitchell DL, Wobb JL, Miller ED, Blakaj DM, Diavolitsis VM, Lee N, Bhatt AD. Platinum‐based regimens versus cetuximab in definitive chemoradiation for human papillomavirus‐unrelated head and neck cancer. International Journal Of Cancer 2019, 147: 107-115. PMID: 31609479, DOI: 10.1002/ijc.32736.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCetuximabChemoradiotherapyCisplatinFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedNeoplasm StagingPapillomaviridaePapillomavirus InfectionsRandomized Controlled Trials as TopicSquamous Cell Carcinoma of Head and NeckSurvival RateConceptsLocoregional failureOverall survivalDistant metastasisReduced hazardMultivariable analysisKaplan-MeierHuman papillomavirus-unrelated headNeck squamous cell carcinomaPlatinum-based regimensSquamous cell carcinomaSuperior locoregional controlCumulative incidence functionDefinitive chemoradiationDefinitive radiotherapyLocoregional controlAdvanced headClinical characteristicsCumulative incidenceConcurrent cetuximabPropensity matchingYear OSCell carcinomaHuman papillomavirusNeck cancerProportional hazards
2018
Wrong to be Right
Kang JJ, Reiter RE, Kummer N, DeKernion J, Steinberg ML, King CR. Wrong to be Right. American Journal Of Clinical Oncology 2018, 41: 1-5. PMID: 26237192, PMCID: PMC6946377, DOI: 10.1097/coc.0000000000000216.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalysis of VarianceCohort StudiesDatabases, FactualDisease-Free SurvivalFollow-Up StudiesHumansKaplan-Meier EstimateMaleMargins of ExcisionMiddle AgedMultivariate AnalysisNeoplasm GradingNeoplasm Recurrence, LocalProportional Hazards ModelsProstatectomyProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesRisk AssessmentSalvage TherapySurvival AnalysisTreatment OutcomeConceptsSalvage radiation therapyRadical prostatectomyT stageCox multivariate analysisIntrinsic risk factorsIatrogenic failuresPostoperative PSASRT PSASalvage radiationBiochemical progressionIndependent predictorsLocal recurrencePreoperative PSARelapse rateBiochemical relapseKaplan-MeierBiochemical recurrenceSurgical approachRP patientsRisk factorsSurgical techniqueGleason gradeRadiation therapySurgical pathologyConsecutive rises
2014
Ultrasensitive Prostate Specific Antigen after Prostatectomy Reliably Identifies Patients Requiring Postoperative Radiotherapy
Kang JJ, Reiter RE, Steinberg ML, King CR. Ultrasensitive Prostate Specific Antigen after Prostatectomy Reliably Identifies Patients Requiring Postoperative Radiotherapy. Journal Of Urology 2014, 193: 1532-1538. PMID: 25463990, PMCID: PMC4527538, DOI: 10.1016/j.juro.2014.11.017.Peer-Reviewed Original ResearchConceptsUltrasensitive prostate specific antigenProstate-specific antigenInitial prostate-specific antigenPostoperative prostate-specific antigenBiochemical relapseSpecific antigenHigh riskRadical prostatectomyPostoperative radiotherapyT stageGleason gradeMultivariate analysisProstate-specific antigen (PSA) recurrenceEventual biochemical failureSpecific antigen recurrenceCox multivariate analysisTraditional risk factorsConventional prostate specific antigenBiochemical failureIdentifies patientsMedian followupMargin statusPathology findingsKaplan-MeierPositive margins